The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

20 August 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Clinical Trial Update

Clinical Trial Site Activation and Commencement of Patient Recruitment

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that the first clinical site for its Phase II study of irinotecan ChemoSeed® for the treatment of glioblastoma has now been formally activated and patient recruitment has started.

Formal site activation represents a significant milestone for ChemoSeed®'s clinical development programme and enables the clinical team to begin identifying, screening and enrolling eligible patients into the study.  

As the study officially transitions into its active clinical phase, the Company's immediate operational focus is the screening and clinical assessment of eligible participants. The next key milestone will be the successful treatment of the first patient with ChemoSeed®, and the Company will provide a further update once this has been achieved.

Professor Christopher McConville, Chief Scientific Officer of CRISM Therapeutics, commented:
"The activation of our first clinical site and opening of the study for patient recruitment is an important milestone for CRISM and the ChemoSeed® programme. We are delighted that the study has now entered active patient recruitment and that the clinical team can begin identifying and screening potential patients."

"We would like to thank the investigators, NHS Trust, clinical site team and our clinical partners for their work, and we look forward to updating shareholders as the study progresses."

Professor Garth Cruickshank, Emeritus Professor of Neurosurgery at the University of Birmingham and member of CRISM's Scientific Advisory Board, added: "Opening this study to patient recruitment is a significant milestone in developing this novel treatment platform. Glioblastoma remains one of the most challenging cancers to treat, with recurrence frequently occurring close to the site of the original tumour despite surgery and subsequent treatment.

 "ChemoSeed has been designed to address this challenge by delivering irinotecan directly into the tumour resection margin at the time of surgery, when the residual tumour burden is at its lowest. This approach has the potential to achieve, safe but sustained, high concentrations of chemotherapy at the site where it is most needed, while limiting systemic exposure with a drug proven to be active against glioblastoma.

"With the clinical site now activated and open to recruitment, we can begin the process of identifying suitable patients for the study and evaluating this approach in the clinical setting. I am very pleased to see the trial reach this stage."

-Ends-

Enquiries:

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.